Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, China.
Oral Dis. 2022 Apr;28(3):600-610. doi: 10.1111/odi.13782. Epub 2021 Feb 9.
The systemic inflammation response index (SIRI) is an independent prognostic factor for many malignant tumors. However, the value of this factor in patients with clinical T1-2N0 (cT1-2N0) oral squamous cell carcinoma (OSCC) is still unclear.
We calculated SIRI of 235 cT1-2N0 OSCC patients from 2013 to 2017. Multivariate cox regression analysis was applied to verify the prognostic significance of SIRI. Kaplan-Meier curves were plotted to analyze the overall survival (OS) and disease-specific survival (DSS) for cT1-2N0 OSCC patients.
According to the optimal cutoff point of SIRI, we divided cT1-2N0 OSCC patients into high SIRI group (SIRI ≥ 1.3) and low SIRI group (SIRI < 1.3). SIRI was an independent prognostic indicator for OS (HR = 2.87; 95% CI = 1.35-6.10; p = .006) and DSS (HR = 2.17; 95% CI = 1.10-4.27; p = .025). High SIRI had a significantly poorer OS (p = .001) and DSS (p = .007) in survival analysis than the low SIRI. Moreover, the prognostic value of SIRI was significantly stronger than neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR).
Preoperative SIRI can be regarded as a meaningful indicator for poor survival of cT1-2N0 OSCC patients, and it is a promising tool to formulate the best individualized treatment for high-risk patients.
全身性炎症反应指数（SIRI）是许多恶性肿瘤的独立预后因素。然而，该因素在临床 T1-2N0（cT1-2N0）口腔鳞状细胞癌（OSCC）患者中的价值尚不清楚。
我们对 2013 年至 2017 年间的 235 例 cT1-2N0 OSCC 患者计算了 SIRI。采用多变量 cox 回归分析验证 SIRI 的预后意义。绘制 Kaplan-Meier 曲线分析 cT1-2N0 OSCC 患者的总生存（OS）和疾病特异性生存（DSS）。
根据 SIRI 的最佳截断点，我们将 cT1-2N0 OSCC 患者分为高 SIRI 组（SIRI≥1.3）和低 SIRI 组（SIRI＜1.3）。SIRI 是 OS（HR=2.87；95%CI=1.35-6.10；p=0.006）和 DSS（HR=2.17；95%CI=1.10-4.27；p=0.025）的独立预后指标。在生存分析中，高 SIRI 患者的 OS（p=0.001）和 DSS（p=0.007）明显较差。此外，SIRI 的预后价值明显强于中性粒细胞与淋巴细胞比值（NLR）和单核细胞与淋巴细胞比值（MLR）。
术前 SIRI 可作为 cT1-2N0 OSCC 患者生存不良的有意义指标，是为高危患者制定最佳个体化治疗方案的有前途工具。
